As of 2025-03-22, the EV/EBITDA ratio of Aclaris Therapeutics Inc (ACRS) is -3.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Aclaris's latest enterprise value is 148.10 mil USD. Aclaris's TTM EBITDA according to its financial statements is -48.45 mil USD. Dividing these 2 quantities gives us the above Aclaris EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 9.5x | 8.4x |
| Forward P/E multiples | 9.4x - 17.0x | 12.8x |
| Fair Price | (3.97) - (4.04) | (4.55) |
| Upside | -348.4% - -352.3% | -384.6% |
| Date | EV/EBITDA |